Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
JAMA · 15.07.2025 · 334 (3) · 229
DOI: 10.1001/jama.2025.7817 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 15.07.2025. Verfasst von Alexis Moscoso und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Swe…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Neurofibrillary Tangles, Positron-Emission Tomography. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCRR NIH HHS, NIDCD NIH HHS.
Abstract (Originalsprache)
Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD).
Objective
To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia).
Results
Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
- Nuclear Medicine Department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota.
- Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
Förderung
- NIA NIH HHS
- NCRR NIH HHS
- NIDCD NIH HHS
- NIMH NIH HHS
- NIAID NIH HHS
- RRD VA
- NIH HHS
- NINDS NIH HHS
Zitieren
APA
Moscoso, A., Heeman, F., Raghavan, S., Costoya-Sánchez, A., van Essen, M., Mainta, I., Camacho, V., Rodríguez-Fonseca, O., Silva-Rodríguez, J., Perissinotti, A., Gu, Y., Yun, J., Peretti, D., Ribaldi, F., Coomans, E. M., Brum, W. S., Grothe, M. J., Aguiar, P., Bischof, G. N., …, & PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative (2025). Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity. JAMA, 334(3), 229. https://doi.org/10.1001/jama.2025.7817
Vancouver
Moscoso A, Heeman F, Raghavan S, Costoya-Sánchez A, van Essen M, Mainta I, et al. Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity. JAMA. 2025;334(3):229. doi:10.1001/jama.2025.7817
BibTeX
@article{Moscoso2025,
author = {Moscoso, Alexis and Heeman, Fiona and Raghavan, Sheelakumari and Costoya-Sánchez, Alejandro and van Essen, Martijn and Mainta, Ismini and Camacho, Valle and Rodríguez-Fonseca, Omar and Silva-Rodríguez, Jesús and Perissinotti, Andrés and Gu, Yuna and Yun, Jihwan and Peretti, Debora and Ribaldi, Federica and Coomans, Emma M and Brum, Wagner S and Grothe, Michel J and Aguiar, Pablo and Bischof, Gérard N and Drzezga, Alexander and Seo, Sang Won and Villeneuve, Sylvia and Malpetti, Maura and O'Brien, John T and Rowe, James B and van de Giessen, Elsmarieke M and Ossenkoppele, Rik and Jagust, William J and Smith, Ruben and Hansson, Oskar and Frisoni, Giovanni B and Garibotto, Valentina and Soleimani-Meigooni, David N and Carrillo, Maria and Dickerson, Bradford C and La Joie, Renaud and Rabinovici, Gil D and Apostolova, Liana G and LaMontagne, Pamela J and Pontecorvo, Michael J and Johnson, Keith A and Sperling, Reisa A and Weiner, Michael W and Petersen, Ronald C and Jack, Clifford R and Vemuri, Prashanthi and Schöll, Michael and PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative, PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative},
title = {Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity},
journal = {JAMA},
year = {2025},
volume = {334},
number = {3},
pages = {229},
doi = {10.1001/jama.2025.7817}
}
EUVIMED